You are currently viewing a new version of our website. To view the old version click .
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 14, Issue 4

August 2007 - 7 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (7)

  • Article
  • Open Access
106 Citations
2,187 Views
13 Pages

Management of Single Brain Metastasis: A Practice Guideline

  • A. Mintz,
  • J. Perry,
  • K. Spithoff,
  • A. Chambers,
  • N. Laperriere and
  • on behalf of the Neuro-oncology Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care

1 August 2007

Questions: Should patients with confirmed single brain metastasis undergo surgical resection? Should patients with single brain metastasis undergoing surgical resection receive adjuvant wholebrain radiation therapy (WBRT)? What is the role of stereot...

  • Article
  • Open Access
17 Citations
2,301 Views
5 Pages

Ifosfamide-Based Combination Chemotherapy in Advanced Soft-Tissue Sarcoma: A Practice Guideline

  • S. Verma,
  • J. Younus,
  • D. Stys–Norman,
  • A.E Haynes,
  • M. Blackstein and
  • The members of the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care

1 August 2007

Questions: In adult patients with inoperable locally advanced or metastatic soft-tissue sarcoma, do combination chemotherapy regimens containing ifosfamide have an advantage in terms of response rate, time to progression, or survival, as compared wit...

  • Article
  • Open Access
55 Citations
1,210 Views
5 Pages

Updated Recommendations from the Canadian National Consensus Meeting on HER2/neu Testing in Breast Cancer

  • W. Hanna,
  • F.P. O’Malley,
  • P. Barnes,
  • R. Berendt,
  • L. Gaboury,
  • A. Magliocco,
  • N. Pettigrew,
  • S. Robertson,
  • S. Sengupta and
  • B. Têtu
  • + 1 author

1 August 2007

Testing for HER2/neu in breast cancer at the time of primary diagnosis is now the standard of care. Accurate and standardized testing methods are of prime importance to ensure the proper classification of the patient’s HER2/neu status. A meeting of p...

  • Article
  • Open Access
39 Citations
1,334 Views
8 Pages

Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

  • R. Buckstein,
  • R. M. Meyer,
  • L. Seymour,
  • J. Biagi,
  • H. MacKay,
  • S. Laurie and
  • E. Eisenhauer

1 August 2007

Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1, 2, 3, and platelet-derived growth f...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729